Search

Displaying results 4791 - 4800 of 7283 in total
  1. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    Garadacimab is a fully human monoclonal antibody targeted against activated factor XII. … [L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema.

  2. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    [L45608,L45618] On March 2023, the FDA granted accelerated approval to retifanlimab for a different indication, the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). … On October 2021, Incyte Biosciences withdrew its application for a marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal.

  3. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. … [A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA.

  4. Drug

    Melperone

    go.drugbank.com/drugs/DB09224
    Investigational

    Melperone has been used for a span of greater than 30 years in the European Union [L1316]. … Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316].

    Categories: Dopamine D2 Receptor AntagonistsProducts: MELPERON 1A PHARMA 50MG, MELPERON 1A PHARM 25MG/5ML
  5. Drug

    Alginic acid

    go.drugbank.com/drugs/DB13518
    ApprovedInvestigationalWithdrawn

    Alginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. … It is present in cell walls of brown algae where it forms a viscous gel when binding with water.

    Mixtures: SUSPENSION ORAL CON SABOR A MENTA, SUSPENSION ORAL CON SABOR A MENTACategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). … [A262924] On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA.

  7. Drug

    Milrinone

    go.drugbank.com/drugs/DB00235
    ApprovedInvestigational

    Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. … [A228323] Milrinone is a second-generation bipyridine phosphodiesterase (PDE) inhibitor created through chemical modification of [amrinone].

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. … [A187991] Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment

  9. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency. … [Peginterferon Alfa-2a]) in Patients With CHD.

  10. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    Eladocagene exuparvovec is a recombinant adeno-associated virus-2 (AAV2)-based gene therapy that expresses human aromatic L-amino acid decarboxylase (AADC), and it is used to treat AADC deficiency, a fatal … [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893]

    Categories: Complex Mixtures